Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)
Phase: PHASE2 | Sponsor: Alan Davis | Compound: Psilocybin
- Status
- recruiting
- Institution
- Alan Davis
- Start date
- 2025-11-20
- End date
- 2026-12-31
- Registry ID
- NCT07216404
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.